Daily Sepsis Research Analysis
Analyzed 48 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies span translational therapy, early-phase clinical innovation, and risk stratification. A bacteria-activated nanoparticle rejuvenates macrophage function to prevent secondary infections in preclinical sepsis, a randomized crossover pilot will test dialysate iron chelation to counter ferroptosis in sepsis-associated AKI, and a large cohort integrates the pan-immune-inflammation value into SIC prognosis with external validation and machine learning.
Research Themes
- Immunomodulatory nanotherapeutics for sepsis-associated secondary infection
- Targeted removal of labile iron to mitigate ferroptosis in sepsis-associated AKI
- Prognostic modeling in sepsis-induced coagulopathy with external validation
Selected Articles
1. FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection.
A transformable, bacteria-activated peptide nanoparticle (BATMAN) exposes tuftsin clusters to engage macrophage Fcγ receptors, enhancing phagocytosis and repolarization. In septic mice with secondary pulmonary infections (including polymicrobial and MDR pathogens), BATMAN improved survival and restored antibacterial immunity, highlighting a therapeutic strategy for sepsis-associated immunosuppression.
Impact: Introduces a first-in-class, conditionally activatable immunomodulatory nanoparticle that simultaneously targets pathogens and reprograms host macrophages, achieving survival benefit in rigorous preclinical sepsis models.
Clinical Implications: If safety and pharmacology translate to humans, BATMAN-like agents could complement antibiotics by reversing sepsis-associated immunosuppression and preventing secondary infections, especially from multidrug-resistant organisms.
Key Findings
- BATMAN undergoes bacterial lipase-triggered inside-out transformation to cluster tuftsin and engage macrophage Fcγ receptors.
- Enhances macrophage phagocytosis and repolarization toward antibacterial phenotypes.
- Improves survival and restores immune responses in cecal slurry-induced septic mice with secondary pulmonary infections, including polymicrobial and MDR pathogens.
Methodological Strengths
- Mechanistically designed, conditionally activatable nanoparticle with defined multi-domain architecture.
- Efficacy demonstrated in vivo in clinically relevant secondary infection models with survival endpoints.
Limitations
- Preclinical animal study without human safety, pharmacokinetics, or dosing data.
- Comparative effectiveness versus standard-of-care antimicrobials or immunoadjuvants not evaluated.
Future Directions: Prioritize GLP toxicology, biodistribution, and PK/PD studies; test in larger animal sepsis models; explore combination with antibiotics; and design early-phase human trials focused on sepsis-associated secondary infection prevention.
Sepsis-associated secondary infection often leads to a high mortality rate. Dysfunctional macrophages are primary contributors to inadequate antimicrobial defense in patients with sepsis-associated immunosuppression. Rejuvenating macrophage antibacterial capacity is beneficial for host defense against secondary infection. Here, we developed "BATMAN" (bacteria-targeted transformable macrophage nanorejuvenator), a self-assembling peptide nanoparticle to tackle sepsis-associated secondary infection by coordinating the arrest of invasive bacteria and rejuvenation of dysfunctional macrophages. BATMAN comprises a bacteria-targeting ubiquicidin peptide domain, bacterial lipase-sensitive cholesteryl hemisuccinate, an assembly-driving FFVLK domain, and the immunoglobulin G-derived tuftsin peptide. Upon activation by bacterial lipase, the particles undergo an inside-out transformation and assembly to expose and cluster the concealed tuftsin peptides for interaction with macrophage Fcγ receptors. Interaction of tuftsin clusters with macrophage Fcγ receptors enhanced bacterial phagocytosis and drove macrophage repolarization. In a cecal slurry-induced septic mouse model with secondary pulmonary infection, BATMAN treatment improved survival rates and rejuvenated the sepsis-compromised immune response to address polymicrobial- and multidrug-resistant pathogen-induced pulmonary infections. These findings suggest that BATMAN holds promise for further development as a therapeutic alternative for sepsis-associated secondary infection.
2. Evaluation of the performance and safety of adding the iron chelator MEX-CD1 to dialysate during continuous veno-venous haemodialysis for removing excess labile iron in intensive care patients with sepsis-associated acute kidney injury - the Iron in Intensive Care trial (
This single-centre randomized, open-label, crossover phase I–II pilot will test whether supplementing CVVHD dialysate with the iron chelator MEX-CD1 enhances removal of labile iron in sepsis-associated AKI. Primary outcome is iron removal performance; secondary outcomes include oxidative stress and inflammation biomarkers and safety through 28 days.
Impact: Targets ferroptosis biology in human sepsis-associated AKI using an innovative dialysate chelation approach within a randomized crossover design, potentially inaugurating a new adjunctive modality.
Clinical Implications: If effective and safe, MEX-CD1–supplemented dialysate could become an adjunct during CVVHD to reduce oxidative injury and improve outcomes in sepsis-associated AKI.
Key Findings
- Randomized, open-label, crossover phase I–II pilot with 14 adults with sepsis-associated AKI requiring CVVHD.
- Primary endpoint: effluent iron concentration to quantify labile iron removal; secondary endpoints include plasma iron clearance, oxidative stress/inflammation biomarkers, trace element loss, and safety to 28 days.
- Intervention: dialysate supplemented with MEX-CD1 (50 mg/L) versus standard dialysate; each patient serves as their own control.
Methodological Strengths
- Randomized crossover design minimizing inter-patient variability as each patient is their own control.
- Mechanistic secondary endpoints (oxidative stress/inflammation biomarkers) alongside performance and safety outcomes.
Limitations
- Single-centre, open-label pilot with small sample size (n=14) limits generalizability and precision.
- Phase I–II design focuses on performance and safety; clinical efficacy endpoints are not powered.
Future Directions: If performance and safety are demonstrated, proceed to multicentre, blinded efficacy trials assessing renal recovery, organ dysfunction, and mortality; optimize dosing and assess trace element balance.
INTRODUCTION: Sepsis-associated acute kidney injury is common in intensive care and is linked to high morbidity and mortality, yet no specific therapy exists beyond supportive care. Excess circulating labile iron contributes to oxidative stress, mitochondrial dysfunction and cell death via ferroptosis. We hypothesise that targeted removal of labile iron during dialysis may reduce this pathogenic process. This study will evaluate the performance and safety of adding a novel iron chelator named MEX-CD1 (Metal EXtraction - Chitosan DOTAGA 1) to dialysate during continuous veno-venous haemodialysis (CVVHD) in critically ill patients with sepsis-associated acute kidney injury. METHODS AND ANALYSIS: This is a single-centre, randomised, open-label, crossover phase I-II pilot study in the intensive care unit of Nîmes University Hospital, France. 14 adult patients with sepsis-associated acute kidney injury requiring renal replacement therapy will receive two consecutive 24-hour CVVHD sessions: one with standard dialysate and one with dialysate supplemented with MEX-CD1 at 50 mg/L. Each patient serves as their own control. The primary outcome is the iron concentration in the effluent to measure iron removal performance. Secondary outcomes include plasma iron clearance, trace element loss, biomarkers of oxidative stress and inflammation, and safety outcomes monitored up to 28 days. Statistical analyses will use paired tests and mixed linear regression models. ETHICS AND DISSEMINATION: Ethical approval has been obtained from the Comité de Protection des Personnes (no. 25.01220.000448) and the French National Agency for Safety of Drugs and Medical Devices (no. 2024-A01530-47). Results will be disseminated through peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER: NCT07236463.
3. Prognostic value of the pan-immune-inflammation value for mortality in sepsis-induced coagulopathy: a Medical Information Mart for Intensive Care study.
In a retrospective MIMIC-IV cohort of 4,554 septic patients, higher PIV was associated with increased 30- and 90-day mortality in SIC with a nonlinear dose-response. An 8-variable nomogram and machine-learning models (best: random forest) showed strong discrimination and were externally validated in a real-world cohort.
Impact: Establishes and externally validates PIV as a prognostic marker in SIC with practical tools (nomogram and ML), enabling early risk stratification and potentially guiding targeted management.
Clinical Implications: PIV can be incorporated into SIC risk assessment to identify high-risk patients for intensified monitoring, anticoagulation evaluation, and individualized supportive strategies.
Key Findings
- High PIV was associated with higher 30- and 90-day mortality in SIC, with a nonlinear positive relationship.
- An 8-variable nomogram achieved AUCs of 0.84 (training) and 0.87 (validation).
- Random forest model performed best (AUC 0.837 training, 0.947 validation), and results were externally validated in an independent hospital cohort with consistent survival trends.
Methodological Strengths
- Large sample size with comprehensive survival and multivariable analyses.
- External validation and use of both traditional statistics and machine learning.
Limitations
- Retrospective design susceptible to residual confounding and selection bias.
- Generalizability may be limited by single external site and healthcare system differences; calibration across settings is needed.
Future Directions: Prospective multicentre validation, dynamic PIV trajectories in SIC, threshold calibration, and impact studies testing whether PIV-guided management improves outcomes.
BACKGROUND: Sepsis is a life-threatening condition characterized by organ dysfunction caused by a dysregulated host response to infection. Its associated coagulopathy, known as sepsis-induced coagulopathy (SIC), significantly increases mortality risk. The pan-immune-inflammation value (PIV), a composite biomarker reflecting systemic immune and inflammatory status, has been linked to prognosis in various diseases. OBJECTIVES: This study aimed to evaluate the prognostic significance of PIV in patients with SIC and to develop predictive models accordingly. METHODS: This retrospective study utilized data from the Medical Information Mart for Intensive Care IV database and included 4554 patients diagnosed with sepsis. Patients were stratified into high- and low-PIV groups based on the median PIV, and clinical characteristics were compared between groups. Kaplan-Meier survival analysis and Cox regression were employed to assess the association between PIV and patient outcomes. Least absolute shrinkage and selection operator regression was used to identify key variables for constructing a nomogram model. Additionally, machine learning algorithms, including random forest, were applied to build and validate predictive models. RESULTS: Patients in the high-PIV group had significantly higher 30-day and 90-day mortality rates. Kaplan-Meier analysis showed that patients with lower PIVs had markedly better survival, and a nonlinear positive correlation was observed between PIV and mortality risk. Least absolute shrinkage and selection operator regression identified 8 key variables, including Acute Physiology Score III, lactate, red cell distribution width, mean corpuscular volume, acute kidney injury, and continuous renal replacement therapy. The nomogram based on these variables achieved areas under the receiver operating characteristic curve of 0.84 and 0.87 in the training and validation cohorts, respectively. Among machine learning models, the random forest algorithm exhibited the best predictive performance, with areas under the curve of 0.837 and 0.947 in the training and validation sets, respectively. External validation using a real-world cohort from Xingtai People's Hospital further confirmed the association between elevated PIV and increased mortality and SIC, with consistent survival trends and nonlinear patterns observed in both Kaplan-Meier and restricted cubic spline analyses. CONCLUSION: To our knowledge, this study is the first to incorporate PIV into the prognostic assessment of patients with SIC. The development of a visual nomogram and machine learning-based models provides clinicians with practical tools for early identification of patients at high risk for SIC, potentially aiding in the optimization of treatment strategies.